Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure

Abstract The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concern...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2021-02, Vol.72 (4), p.541-552
Hauptverfasser: Rhee, Chanu, Chiotos, Kathleen, Cosgrove, Sara E, Heil, Emily L, Kadri, Sameer S, Kalil, Andre C, Gilbert, David N, Masur, Henry, Septimus, Edward J, Sweeney, Daniel A, Strich, Jeffrey R, Winslow, Dean L, Klompas, Michael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 552
container_issue 4
container_start_page 541
container_title Clinical infectious diseases
container_volume 72
creator Rhee, Chanu
Chiotos, Kathleen
Cosgrove, Sara E
Heil, Emily L
Kadri, Sameer S
Kalil, Andre C
Gilbert, David N
Masur, Henry
Septimus, Edward J
Sweeney, Daniel A
Strich, Jeffrey R
Winslow, Dean L
Klompas, Michael
description Abstract The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics. This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.
doi_str_mv 10.1093/cid/ciaa059
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8189682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciaa059</oup_id><sourcerecordid>2399838578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqVw4o58QkUo4D-J1-4BqZQFKrWwsL1bs_aka0jiYCcr7dfiE-LVbiu4cLBmpPn5zdO8onjO6BtGtXhrvcsPgNb6QXHMajErZa3Zw9zTWpWVEuqoeJLSD0oZU7R-XBwJLmaVkuy4-H3ZN2hHH6ZEPviEkDCRZbAexy0JDTnvMHoLZBGSz1RPFjBgPCPf0Yauw96hy_3GpzxLZAxkXCP5AjsUWrLEDUbMZUg-Eejdrh29Jct1sD_JHGK7JdfQwy1mrZG8n3rXIjldzhcle3X379sErc92rrO7KeLT4lEDbcJnh3pS3Hyc31x8Lq--frq8OL8qbcX4WHLQFUq2srzhSkDleCNWglJJBaC2lZQ1aLWSusmHs5JVaJngTDiHlWNOnBTv9rLDtOrQ2ewvQmuG6DuIWxPAm38nvV-b27AxiiktFc8CpweBGH5NmEbT-WSxbaHHfG7DhdY5m3qmMvp6j9oYUorY3K9h1OxCNjlkcwg50y_-dnbP3qWagZd7IEzDf5X-AM1Gs_c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399838578</pqid></control><display><type>article</type><title>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Rhee, Chanu ; Chiotos, Kathleen ; Cosgrove, Sara E ; Heil, Emily L ; Kadri, Sameer S ; Kalil, Andre C ; Gilbert, David N ; Masur, Henry ; Septimus, Edward J ; Sweeney, Daniel A ; Strich, Jeffrey R ; Winslow, Dean L ; Klompas, Michael</creator><creatorcontrib>Rhee, Chanu ; Chiotos, Kathleen ; Cosgrove, Sara E ; Heil, Emily L ; Kadri, Sameer S ; Kalil, Andre C ; Gilbert, David N ; Masur, Henry ; Septimus, Edward J ; Sweeney, Daniel A ; Strich, Jeffrey R ; Winslow, Dean L ; Klompas, Michael</creatorcontrib><description>Abstract The Centers for Medicare &amp; Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics. This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciaa059</identifier><identifier>PMID: 32374861</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Aged ; Anti-Bacterial Agents - therapeutic use ; Communicable Diseases - drug therapy ; Humans ; Major and Commentaries ; Medicare ; Quality Indicators, Health Care ; Reproducibility of Results ; Sepsis - diagnosis ; Sepsis - drug therapy ; Shock, Septic - diagnosis ; Shock, Septic - drug therapy ; United States</subject><ispartof>Clinical infectious diseases, 2021-02, Vol.72 (4), p.541-552</ispartof><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020. 2020</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</citedby><cites>FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</cites><orcidid>0000-0002-6489-6294 ; 0000-0002-4420-9004</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32374861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rhee, Chanu</creatorcontrib><creatorcontrib>Chiotos, Kathleen</creatorcontrib><creatorcontrib>Cosgrove, Sara E</creatorcontrib><creatorcontrib>Heil, Emily L</creatorcontrib><creatorcontrib>Kadri, Sameer S</creatorcontrib><creatorcontrib>Kalil, Andre C</creatorcontrib><creatorcontrib>Gilbert, David N</creatorcontrib><creatorcontrib>Masur, Henry</creatorcontrib><creatorcontrib>Septimus, Edward J</creatorcontrib><creatorcontrib>Sweeney, Daniel A</creatorcontrib><creatorcontrib>Strich, Jeffrey R</creatorcontrib><creatorcontrib>Winslow, Dean L</creatorcontrib><creatorcontrib>Klompas, Michael</creatorcontrib><title>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract The Centers for Medicare &amp; Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics. This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.</description><subject>Aged</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Communicable Diseases - drug therapy</subject><subject>Humans</subject><subject>Major and Commentaries</subject><subject>Medicare</subject><subject>Quality Indicators, Health Care</subject><subject>Reproducibility of Results</subject><subject>Sepsis - diagnosis</subject><subject>Sepsis - drug therapy</subject><subject>Shock, Septic - diagnosis</subject><subject>Shock, Septic - drug therapy</subject><subject>United States</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxSMEoqVw4o58QkUo4D-J1-4BqZQFKrWwsL1bs_aka0jiYCcr7dfiE-LVbiu4cLBmpPn5zdO8onjO6BtGtXhrvcsPgNb6QXHMajErZa3Zw9zTWpWVEuqoeJLSD0oZU7R-XBwJLmaVkuy4-H3ZN2hHH6ZEPviEkDCRZbAexy0JDTnvMHoLZBGSz1RPFjBgPCPf0Yauw96hy_3GpzxLZAxkXCP5AjsUWrLEDUbMZUg-Eejdrh29Jct1sD_JHGK7JdfQwy1mrZG8n3rXIjldzhcle3X379sErc92rrO7KeLT4lEDbcJnh3pS3Hyc31x8Lq--frq8OL8qbcX4WHLQFUq2srzhSkDleCNWglJJBaC2lZQ1aLWSusmHs5JVaJngTDiHlWNOnBTv9rLDtOrQ2ewvQmuG6DuIWxPAm38nvV-b27AxiiktFc8CpweBGH5NmEbT-WSxbaHHfG7DhdY5m3qmMvp6j9oYUorY3K9h1OxCNjlkcwg50y_-dnbP3qWagZd7IEzDf5X-AM1Gs_c</recordid><startdate>20210216</startdate><enddate>20210216</enddate><creator>Rhee, Chanu</creator><creator>Chiotos, Kathleen</creator><creator>Cosgrove, Sara E</creator><creator>Heil, Emily L</creator><creator>Kadri, Sameer S</creator><creator>Kalil, Andre C</creator><creator>Gilbert, David N</creator><creator>Masur, Henry</creator><creator>Septimus, Edward J</creator><creator>Sweeney, Daniel A</creator><creator>Strich, Jeffrey R</creator><creator>Winslow, Dean L</creator><creator>Klompas, Michael</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6489-6294</orcidid><orcidid>https://orcid.org/0000-0002-4420-9004</orcidid></search><sort><creationdate>20210216</creationdate><title>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</title><author>Rhee, Chanu ; Chiotos, Kathleen ; Cosgrove, Sara E ; Heil, Emily L ; Kadri, Sameer S ; Kalil, Andre C ; Gilbert, David N ; Masur, Henry ; Septimus, Edward J ; Sweeney, Daniel A ; Strich, Jeffrey R ; Winslow, Dean L ; Klompas, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-2a94e61bc2f283a4d2f3b300603ae9c4665a98b69f059c614ec13213dde4d1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Communicable Diseases - drug therapy</topic><topic>Humans</topic><topic>Major and Commentaries</topic><topic>Medicare</topic><topic>Quality Indicators, Health Care</topic><topic>Reproducibility of Results</topic><topic>Sepsis - diagnosis</topic><topic>Sepsis - drug therapy</topic><topic>Shock, Septic - diagnosis</topic><topic>Shock, Septic - drug therapy</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rhee, Chanu</creatorcontrib><creatorcontrib>Chiotos, Kathleen</creatorcontrib><creatorcontrib>Cosgrove, Sara E</creatorcontrib><creatorcontrib>Heil, Emily L</creatorcontrib><creatorcontrib>Kadri, Sameer S</creatorcontrib><creatorcontrib>Kalil, Andre C</creatorcontrib><creatorcontrib>Gilbert, David N</creatorcontrib><creatorcontrib>Masur, Henry</creatorcontrib><creatorcontrib>Septimus, Edward J</creatorcontrib><creatorcontrib>Sweeney, Daniel A</creatorcontrib><creatorcontrib>Strich, Jeffrey R</creatorcontrib><creatorcontrib>Winslow, Dean L</creatorcontrib><creatorcontrib>Klompas, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rhee, Chanu</au><au>Chiotos, Kathleen</au><au>Cosgrove, Sara E</au><au>Heil, Emily L</au><au>Kadri, Sameer S</au><au>Kalil, Andre C</au><au>Gilbert, David N</au><au>Masur, Henry</au><au>Septimus, Edward J</au><au>Sweeney, Daniel A</au><au>Strich, Jeffrey R</au><au>Winslow, Dean L</au><au>Klompas, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2021-02-16</date><risdate>2021</risdate><volume>72</volume><issue>4</issue><spage>541</spage><epage>552</epage><pages>541-552</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract The Centers for Medicare &amp; Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) measure has appropriately established sepsis as a national priority. However, the Infectious Diseases Society of America (IDSA and five additional endorsing societies) is concerned about SEP-1’s potential to drive antibiotic overuse because it does not account for the high rate of sepsis overdiagnosis and encourages aggressive antibiotics for all patients with possible sepsis, regardless of the certainty of diagnosis or severity of illness. IDSA is also concerned that SEP-1’s complex “time zero” definition is not evidence-based and is prone to inter-observer variation. In this position paper, IDSA outlines several recommendations aimed at reducing the risk of unintended consequences of SEP-1 while maintaining focus on its evidence-based elements. IDSA’s core recommendation is to limit SEP-1 to septic shock, for which the evidence supporting the benefit of immediate antibiotics is greatest. Prompt empiric antibiotics are often appropriate for suspected sepsis without shock, but IDSA believes there is too much heterogeneity and difficulty defining this population, uncertainty about the presence of infection, and insufficient data on the necessity of immediate antibiotics to support a mandatory treatment standard for all patients in this category. IDSA believes guidance on managing possible sepsis without shock is more appropriate for guidelines that can delineate the strengths and limitations of supporting evidence and allow clinicians discretion in applying specific recommendations to individual patients. Removing sepsis without shock from SEP-1 will mitigate the risk of unnecessary antibiotic prescribing for noninfectious syndromes, simplify data abstraction, increase measure reliability, and focus attention on the population most likely to benefit from immediate empiric broad-spectrum antibiotics. This Infectious Diseases Society of America position paper outlines several recommendations aimed at reducing the risk of unintended consequences from the national Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) quality measure, while maintaining focus on its evidence-based elements.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32374861</pmid><doi>10.1093/cid/ciaa059</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6489-6294</orcidid><orcidid>https://orcid.org/0000-0002-4420-9004</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2021-02, Vol.72 (4), p.541-552
issn 1058-4838
1537-6591
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8189682
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Aged
Anti-Bacterial Agents - therapeutic use
Communicable Diseases - drug therapy
Humans
Major and Commentaries
Medicare
Quality Indicators, Health Care
Reproducibility of Results
Sepsis - diagnosis
Sepsis - drug therapy
Shock, Septic - diagnosis
Shock, Septic - drug therapy
United States
title Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A19%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infectious%20Diseases%20Society%20of%20America%20Position%20Paper:%20Recommended%20Revisions%20to%20the%20National%20Severe%20Sepsis%20and%20Septic%20Shock%20Early%20Management%20Bundle%20(SEP-1)%20Sepsis%20Quality%20Measure&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Rhee,%20Chanu&rft.date=2021-02-16&rft.volume=72&rft.issue=4&rft.spage=541&rft.epage=552&rft.pages=541-552&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciaa059&rft_dat=%3Cproquest_pubme%3E2399838578%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399838578&rft_id=info:pmid/32374861&rft_oup_id=10.1093/cid/ciaa059&rfr_iscdi=true